The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works.
Read More Aduhelm (Drug), Biogen Inc, Drugs (Pharmaceuticals), Alzheimer’s Disease, Clinical Trials, Food and Drug Administration, Prices (Fares, Fees and Rates), Recalls and Bans of Products, Regulation and Deregulation of Industry, Medicare
